“I had a positive experience working with your site. During the close-out process, several documents were outstanding in the sponsor’s files. When I called to follow up, the SC and Regulatory person were out of office. Be that as it may, another staff member, Lora, took up the torch and obtained all the requested documents the same day. Other sites would have outright refused, saying it was not their responsibility, but not IDR.”
Site Strengths
- Experienced research coordinators with a special interest in diabetes
- Experienced investigators with 100+ clinical trials started
- High-quality research performance (FDA audit in 2017 with no findings)
- First ever research-based patient portal
- Multiple community relationships providing referrals for research
- Ability to use a Central IRB
- Clinical trial management software ensuring efficient organization of all research activities
We are a multi-center site in Central Iowa performing research in diabetes, diabetes-related conditions, and hormonal disorders.
Type 2 Diabetes
Type 1 Diabetes
Pumps, CGMs, Glucose Meters
NASH
Retinopathy
Kidney Disease
Obesity
Men’s Health (Low-T & Erectile Dysfunction)
Cardiovascular Disease
Partners We’ve Worked With
Recruitment History
Iowa Diabetes Research has a strong history of success in trial recruitment, having over-recruited for a majority of studies we have done to date.
Our Patient Qualifier platform allows us to efficiently and effectively recruit study participants using real-time health data and communication features.
Most of our research patients join another study with us after they finish their current study because of our caring, passionate, and patient-centered staff.
| Company/Medication | Enrollment Goal | Screened | Randomized | % Enrollment |
|---|---|---|---|---|
| Medtronic/Pump use in T1D | 12 | 51 | 41 | 342% |
| GlaxoSmithKline/CV outcomes | 10 | 31 | 28 | 280% |
| Gan and Lee/ Biosimilar insulin glargine in T2D | 12 | 31 | 23 | 192% |
| Lilly/T2DM ultra rapid acting formula insulin lispro | 8 | 24 | 13 | 163% |
| Gan and Lee/ Biosimilar insulin glargine in T1D | 12 | 27 | 19 | 158% |
| Novo Nordisk/GLP-1 use for treatment of obesity | 7 | 16 | 11 | 157% |
| Lilly/T1DM ultra rapid acting formula insulin lispro | 13 | 31 | 19 | 146% |
| Boehringer Ingelheim/SGLT-2 in T1D | 36 | 50 | 48 | 133% |
| Dexcom/CGM use in T1D and T2D | 50 | 59 | 55 | 110% |
